Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study

• DOI: 10.1002/jbmr.2315
• Publication Date: 2014-07-17T19:51:23Z
• Authors: Joy N Tsai; Alexander V Uihlein; Sherri-Ann M Burn...; Robert M Neer; Yuli Zhu; Nicholas Derrico; Hang Lee; Mary L Bouxsein; Benjamin Z Leder
• Keywords: Teriparatide; Denosumab

ABSTRACT Combined teriparatide and denosumab increases spine hip bone mineral density more than either drug alone. The effect of this combination on skeletal microstructure microarchitecture, however, is unknown. Because microarchitecture are important components integrity, we performed high-resolution peripheral quantitative computed tomography (HR-pQCT) assessments at the distal tibia radius in postmenopausal osteoporotic women randomized to receive 20 µg daily (n = 31), 60 mg every 6 months 33), or both 30) for 12 months. In group, total volumetric (vBMD) did not change anatomic site but increased other groups sites. increase vBMD was greater group (3.1 ± 2.2%) (2.2 1.9%) (–0.3 (p < 0.02 comparisons). Cortical decreased by 1.6 1.9% 0.9 2.8% whereas it Tibia cortical (1.5 1.5%) monotherapy 0.04 thickness groups. (5.4 3.9%) 0.01 radial porosity 20.9 37.6% 5.6 9.9% two Bone stiffness failure load, as estimated finite element analysis, Together, these findings suggest that use improves HR-pQCT measures quality alone may be significant clinical benefit treatment osteoporosis. © 2014 American Society Mineral Research.